Quest Diagnostics Incorporated (NYSE:DGX), a prominent provider of diagnostic testing and information services, has hit a record-breaking share price of $180.11, pushing the company’s market capitalization to nearly $20 billion. Analysts currently view the stock as trading above its estimated fair value, signaling robust investor confidence.
The achievement follows a year of steady growth, during which Quest delivered a total return of 31.86% and maintained low stock price volatility. The company has consistently rewarded shareholders, sustaining dividend payments for 22 consecutive years with a current yield of 1.79%.
The new all-time high coincides with a strong Q1 2025 earnings report. Quest reported adjusted earnings per share of $2.21, outpacing analyst projections of $2.16. Revenue also topped expectations, coming in at $2.65 billion—a 12.1% increase year-over-year.
This financial strength led Fitch Ratings to upgrade the company’s Long-Term Issuer Default Rating to ‘BBB+’ with a stable outlook, citing consistent operational results and disciplined growth. In response, JPMorgan raised its price target from $180 to $190 and adjusted EPS forecasts for 2025 and 2026 while maintaining a Neutral rating.
At the company’s 2025 Annual Meeting, shareholders voted to approve executive compensation plans and re-elected directors. They also ratified the appointment of PricewaterhouseCoopers as the company’s independent auditor for the fiscal year. A proposal to allow shareholders to call special meetings did not pass.
Overall, Quest’s performance reflects strong market positioning and investor trust in its strategic trajectory and financial stewardship.